期刊
THERAPEUTICS AND CLINICAL RISK MANAGEMENT
卷 9, 期 -, 页码 177-190出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/TCRM.S30947
关键词
teriflunomide; multiple sclerosis; clinical trials; review
资金
- Teva Neurosciences
- EMD-Serono
- Actelion
- Biogen Idec
- Celgene
- Genzyme
- Sanofi-Aventis
- EMD Merck Serono
- Abbott Labs
- Teva Pharmaceuticals
- Bayer
- Genentech
- Lilly
- Roche
- Novartis
- MS Society of Canada
- NIH
- Direct MS
There are a number of oral agents emerging as potential disease-modifying agents in multiple sclerosis (MS). Among these investigational agents, teriflunomide has shown promise in large, multicenter, phase III clinical trials with respect to safety and efficacy in relapsing MS patients, and is the latest disease-modifying agent approved for use in MS patients in the United States. This review will summarize teriflunomide's historical development, clinical pharmacology, studies in animals, clinical trials, and safety data, and will end with a discussion of the role of teriflunomide in MS in the context of existing treatment options.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据